Kidney Problems in People With Crohn's Disease or Ulcerative Colitis
Compares how often kidney problems occur in adults with inflammatory bowel disease versus others.
Plain-language title generated from the registry record
Registry title: Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD)
Key facts
- Where
- Warsaw, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07593352, who can take part
Where in Poland
- National Medical Institute of the Ministry of the Interior and Administration, Clinic of Gastroenterology and Internal DiseasesWarsaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
- Trial code
- NCT07593352
- Record updated
- 18 May 2026
- Original description
The NEPHRO-IBD study is a multicenter prospective observational study designed to evaluate the prevalence of renal dysfunction and renal complications in adult patients with inflammatory bowel disease (IBD) compared with individuals from the general population. Although extraintestinal manifestations are common in IBD, renal involvement remains relatively underrecognized and insufficiently studied.Read full original descriptionShow less
A Multicenter, Prospective, Observational Study Comparing the Prevalence of Renal Dysfunction in Adult Patient With Inflammatory Bowel Disease Between General Population: The NEPHRO-IBD Study.
The NEPHRO-IBD study is a multicenter prospective observational study designed to evaluate the prevalence of renal dysfunction and renal complications in adult patients with inflammatory bowel disease (IBD) compared with individuals from the general population. Although extraintestinal manifestations are common in IBD, renal involvement remains relatively underrecognized and insufficiently studied.
The study will recruit approximately 6,000 participants, including 3,000 patients with confirmed IBD (Crohn's disease or ulcerative colitis) and 3,000 individuals without IBD serving as a control group. Participants will undergo routine clinical assessment, including laboratory tests, urinalysis with measurement of the albumin-to-creatinine ratio (ACR), and imaging evaluation of the kidneys and urinary tract. Disease activity in patients with IBD will be assessed using validated clinical indices.
The study will also evaluate the relationship between renal dysfunction and disease activity, medications used in IBD treatment, and comorbidities. The results of this study are expected to improve the understanding of renal complications in patients with IBD and support earlier identification and management of kidney disease in this population.
Inclusion: Age over 18 years; Confirmed IBD based on the overall clinical picture and endoscopic examination, or no IBD (control group without IBD); Consent to participate in the study; Cognitive abilities sufficient to complete the questionnaires.
Exclusion: in women, menstruation (urinalysis can be performed 3 days before the onset and 3 days after the end of menstruation); extreme physical exertion within 7 days before the test (marathons, half-marathons, triathlons) and intense physical exertion - strength training - within 1 day before the test. [moderate physical exertion such as walking, swimming, or cycling is not a contraindication]. • Excessive alcohol consumption 14 days before the study; Use of nephrotoxic medications* within a month before and during the study; Use of angiotensin inhibitors, sartans, or flozins that were introduced into treatment within <3 months; *Nephrotoxic drugs:; Nonsteroidal anti-inflammatory drugs (NSAIDs) - occasional use is not contraindicated, but use for ≥ 10 days is an exclusion criterion; Antituberculosis drugs (rifampicin, ethambutol, isoniazid); Antiviral drugs (acyclovir); Oncology drugs (cisplatin); diabetes; dysuric symptoms suggestive of urinary tract infections; other serious comorbidities whose presence or exacerbation may cause abnormalities in laboratory tests suggesting kidney disease; previous surgery whose presence may cause abnormalities in laboratory tests suggesting kidney disease; age under 18 or over 80; refusal to participate in all procedures performed in the study; pregnancy; Inability to perform necessary tests: e.g., inability to perform an imaging test; Unavailability of data: if the study is based on registry data, exclusion of individuals for whom there is incomplete data; Dehydration; Gold salts; Penicillamine; Interferon alpha; Pamidronate; Biseptol; Anticonvulsants (carbamazepine, diazepam, phenobarbital); Cyclosporine A, tacrolimus; Chinese herbs.